Repatha Side Effects: Incidence Rates Across Clinical Trials

How Common Are Repatha Side Effects? The Short Answer

Across the key FOURIER cardiovascular outcomes trial (N=27,564), evolocumab produced adverse event rates that were statistically indistinguishable from placebo for most categories. The drug's tolerability profile is one of the reasons the 2022 ACC/AHA Guideline on Cholesterol Management lists PCSK9 inhibitors as an option for high-risk patients who cannot achieve LDL-C targets on maximally tolerated statin therapy alone [1].

The side effects that do occur fall into three broad categories: injection site reactions, upper respiratory symptoms, and rare but clinically notable events such as hypersensitivity reactions. Each category has a specific incidence figure from a named trial, and understanding those numbers helps prescribers and patients set realistic expectations.

What the FDA Label Says

The FDA-approved prescribing information for evolocumab lists the following adverse reactions occurring in at least 5% of patients and more frequently than placebo in controlled studies: nasopharyngitis (10.5%), upper respiratory tract infection (8.8%), influenza (8.1%), back pain (5.5%), and injection site reactions (3.2%) [2]. The label notes that these figures were drawn from the PROFICIO program, a series of Phase 3 trials enrolling more than 6,000 patients across multiple hyperlipidemia subtypes.

Discontinuation as a Tolerability Marker

Drug discontinuation due to adverse events is one of the cleanest tolerability metrics. In FOURIER, 2.5% of patients in the evolocumab group discontinued due to adverse events, identical to the 2.5% rate in the placebo group [3]. That parity suggests that, at the population level, few patients stop taking Repatha because of side effects specifically attributable to the drug.

Injection Site Reactions: Incidence and Characteristics

Injection site reactions are the most frequently cited adverse event by patients starting evolocumab. They are generally mild and transient.

Incidence by Trial

In the pooled PROFICIO Phase 3 program, injection site reactions occurred in 3.2% of evolocumab-treated patients versus 2.9% of placebo recipients [2]. In the FOURIER trial specifically, the incidence was 1.9% versus 1.4% for placebo, a small absolute difference of 0.5 percentage points [3]. Reactions typically include erythema, pain, bruising, and localized swelling at the injection site.

In a dedicated 12-week injection tolerability sub-study within PROFICIO (N=629), 87.5% of patients rated the autoinjector as "easy" or "very easy" to use, and 96.3% reported willingness to continue self-injection [4]. The 27-mg/mL and 140-mg/mL formulations were both tested; the 140-mg/mL prefilled syringe showed slightly higher rates of transient stinging.

Clinical Management

Rotating injection sites between the abdomen, thigh, and upper arm is the standard approach to minimizing local reactions. Allowing the device to reach room temperature for 30 minutes before injection reduces stinging, according to Amgen's prescribing guidance [2]. Severe or persistent injection site reactions warrant clinical evaluation to rule out hypersensitivity.

Musculoskeletal Side Effects: Myalgia and Back Pain

Statin-related myalgia affects 5 to 10% of patients on standard statin doses, making musculoskeletal complaints a common reason patients switch or add PCSK9 inhibitor therapy. Understanding evolocumab's own musculoskeletal signal matters for distinguishing drug effect from residual statin effect.

Back Pain and Arthralgia in FOURIER

Back pain occurred in 5.5% of evolocumab patients versus 5.0% of placebo patients in controlled PROFICIO trials, a difference of 0.5 percentage points [2]. Arthralgia was reported in 3.0% vs. 2.8% for placebo. These figures do not reach the threshold for a statistically significant drug-attributable signal.

Myalgia Specifically

No significant excess myalgia signal attributable to evolocumab was identified in FOURIER [3]. A separate meta-analysis of four Phase 3 PCSK9 inhibitor trials published in the Journal of the American College of Cardiology (N=24,000+) found no increase in creatine kinase elevation or clinically significant myopathy with PCSK9 inhibitor use compared to placebo [5]. This finding is clinically relevant for the large population of statin-intolerant patients who are candidates for evolocumab monotherapy.

Clinical Decision Framework: Distinguishing Statin Myalgia from Evolocumab-Attributable Musculoskeletal Complaints

| Feature | Statin Myalgia | Evolocumab-Attributed | |---|---|---| | Onset after initiation | Days to weeks | Days to weeks | | CK elevation | Often present (>3x ULN in severe cases) | Rare, not exceeding baseline | | Distribution | Proximal, symmetric | Diffuse back pain, non-specific | | Resolves on drug holiday | Yes (typically 2-4 weeks) | Yes, but statin confound may persist | | Trial-level incidence excess vs. Placebo | Varies by statin/dose | <1 percentage point in FOURIER |

Neurocognitive Effects: What the EBBINGHAUS Trial Found

Early post-market reports and FAERS data raised concern about possible neurocognitive effects of PCSK9 inhibitors, including memory impairment and confusion. The FDA added a class warning in 2017, prompting a formal investigation.

EBBINGHAUS Sub-Study Design and Results

EBBINGHAUS was a pre-specified cognitive sub-study of FOURIER that enrolled 1,204 patients and used validated neuropsychological testing (Cambridge Neuropsychological Test Automated Battery, or CANTAB) over a median 19 months [6]. Spatial working memory strategy scores, the primary endpoint, showed no significant difference between evolocumab and placebo (least-squares mean difference 0.004, 95% CI -0.198 to 0.206, P=0.97) [6].

The incidence of treatment-emergent neurocognitive adverse events was 0.9% in the evolocumab arm versus 0.8% in placebo. The authors concluded that the findings did not support a causal relationship between evolocumab and cognitive impairment.

FDA Position Post-EBBINGHAUS

The FDA reviewed the EBBINGHAUS data and updated the class labeling for PCSK9 inhibitors in 2018, retaining a precautionary statement but acknowledging that controlled trial data did not confirm the signal seen in FAERS spontaneous reports [7]. Prescribers should be aware that FAERS data carries inherent reporting bias and does not establish causation.

Cardiovascular and Serious Adverse Events in FOURIER

FOURIER was a randomized, double-blind, placebo-controlled trial of evolocumab 140 mg every two weeks or 420 mg monthly in 27,564 patients with established atherosclerotic cardiovascular disease on optimized statin therapy. The primary safety outcome was the rate of serious adverse events.

Overall Serious Adverse Event Rates

Serious adverse events occurred in 24.8% of evolocumab patients and 24.7% of placebo patients over a median 2.2 years of follow-up, an absolute difference of 0.1 percentage points [3]. This near-identical rate across a trial of this size is the strongest single piece of evidence for evolocumab's favorable safety profile.

Hemorrhagic Stroke

One concern with aggressive LDL lowering has been whether very low LDL-C levels increase hemorrhagic stroke risk. In FOURIER, hemorrhagic stroke occurred in 0.2% of patients in both arms [3]. A subsequent patient-level meta-analysis of FOURIER and the ODYSSEY OUTCOMES trial (alirocumab, N=18,924) published in The Lancet found no significant increase in hemorrhagic stroke risk with LDL-C levels below 20 mg/dL [8].

New-Onset Diabetes

Statin therapy carries a well-documented 10 to 12% relative risk increase for new-onset type 2 diabetes. FOURIER found no statistically significant increase in new-onset diabetes with evolocumab versus placebo (8.1% vs. 7.7%, P=0.26) [3]. This finding was consistent across pre-specified subgroups including patients with pre-diabetes at baseline.

Allergic and Hypersensitivity Reactions

Hypersensitivity reactions to evolocumab are rare but documented in both clinical trials and post-market surveillance.

Trial-Level Data

In the PROFICIO program, hypersensitivity reactions (including rash, urticaria, and eczema) occurred in 5.1% of evolocumab patients versus 4.7% of placebo recipients, a non-significant difference [2]. Angioedema was not reported at a meaningful frequency in clinical trials but has appeared in FAERS post-marketing reports.

Post-Market FAERS Data

The FDA FAERS database contains post-marketing reports of serious hypersensitivity reactions including angioedema, hypersensitivity vasculitis, and anaphylaxis for evolocumab [7]. Because FAERS uses voluntary reporting, these figures cannot be converted into population-level incidence rates. Cases of severe hypersensitivity reactions require immediate discontinuation of evolocumab and appropriate medical management, as stated in the current FDA label.

Specific Immunogenicity

Binding antibodies to evolocumab developed in 0.3% of patients in the PROFICIO Phase 3 studies. Neutralizing antibodies were detected in 0.1% [2]. Neither binding nor neutralizing antibody formation was associated with altered pharmacokinetics or loss of LDL-lowering efficacy in these trials, though monitoring for loss of effect over time is clinically reasonable.

Liver and Renal Safety

Concerns about hepatic and renal effects with lipid-lowering agents arise frequently from patients and providers.

Hepatic Safety Data

Liver enzyme elevations greater than three times the upper limit of normal (ULN) occurred in 0.4% of evolocumab patients versus 0.3% of placebo patients in PROFICIO [2]. No cases of drug-induced liver injury meeting Hy's Law criteria were reported in the FOURIER program [3]. The FDA label does not require routine liver function monitoring during evolocumab therapy.

Renal Safety Data

Serum creatinine and eGFR did not differ significantly between evolocumab and placebo in FOURIER [3]. A pre-specified renal sub-study of FOURIER (N=3,992 patients with CKD at baseline, eGFR <60 mL/min/1.73m²) published in the Journal of the American Society of Nephrology found that evolocumab reduced major adverse cardiovascular events by 21% in patients with CKD without worsening kidney function over the follow-up period [9].

Side Effects in Special Populations

Patients with Homozygous Familial Hypercholesterolemia (HoFH)

In the TESLA Part B trial (N=50 HoFH patients, 12 weeks), adverse events occurred in 72% of evolocumab patients and 76% of placebo patients [10]. No unique safety signal emerged in this genetically distinct population, though the small sample size limits interpretation. Nasopharyngitis and headache were the most commonly reported events.

Elderly Patients

Patients 65 years and older comprised approximately 30% of the FOURIER population. A pre-specified age sub-group analysis found no significant difference in adverse event rates between older and younger participants [3]. Dose adjustment for age is not required per the FDA label.

Patients with Type 2 Diabetes

Approximately 37% of FOURIER participants had diabetes at baseline. The adverse event profile in this subgroup did not differ meaningfully from the overall population, and the cardiovascular benefit (15% relative risk reduction in the primary composite endpoint) was preserved [3].

Long-Term Safety: FOURIER Open-Label Extension

The FOURIER-OLE (Open-Label Extension) study followed 6,635 patients for up to 5 additional years of evolocumab exposure beyond the parent FOURIER trial, for a maximum total evolocumab exposure of approximately 8 years [11].

Key OLE Safety Findings

In FOURIER-OLE, the incidence of adverse events per 100 patient-years did not increase with longer exposure. The rate of serious adverse events was 18.4 per 100 patient-years in year 1 and 16.2 per 100 patient-years in years 4 to 5, suggesting no accumulation of harm over time [11]. Neurocognitive event rates remained low and did not increase with prolonged very low LDL-C exposure. These data were published in the New England Journal of Medicine in 2023.

The trial investigators noted: "Long-term exposure to evolocumab, with resulting very low LDL cholesterol levels, was not associated with an increased risk of adverse events, including neurocognitive events or new-onset diabetes, over a follow-up of up to 8.4 years" [11].

Comparing Evolocumab and Alirocumab Side Effect Profiles

Both evolocumab (Repatha) and alirocumab (Praluent) are approved PCSK9 inhibitors, and clinicians frequently compare their safety profiles.

Head-to-Head Data

No direct randomized head-to-head safety trial comparing evolocumab and alirocumab has been completed. The ODYSSEY OUTCOMES trial of alirocumab (N=18,924, median 2.8 years) reported injection site reactions in 3.8% of alirocumab patients versus 2.1% of placebo patients, a somewhat higher absolute difference than the 0.5-percentage-point difference seen in FOURIER [12]. Nasopharyngitis rates were similar: 11.1% versus 10.7% for alirocumab versus placebo in ODYSSEY OUTCOMES [12].

Practical Takeaway

The two agents share a comparable safety profile based on available data. Choice between them may depend on dosing interval (alirocumab is dosed every two weeks; evolocumab offers both every-two-week and monthly options), formulary status, and individual patient preference for device type.